Inside the Mitochondria: How Type 1 Diabetes Damages Cells' Power Plants

Type 1 diabetes is well understood as an autoimmune disease in which the body attacks and destroys insulin-producing beta cells. But researchers increasingly recognize that damage extends deeper—into the mitochondria, the tiny structures inside nearly every cell that convert nutrients into energy.

A comprehensive review of scientific literature identified five specific ways mitochondria malfunction in Type 1 diabetes. First, oxidative stress—an overload of harmful molecules—damages mitochondrial components. Second, cells struggle to produce adequate amounts of ATP, the molecule that powers cellular work. Third, the quality control systems that remove damaged proteins break down. Fourth, damaged cells die at elevated rates through a process called apoptosis. Finally, the normal movement and division of mitochondria becomes disrupted.

These problems aren't just academic. Mitochondrial dysfunction contributes not only to Type 1 diabetes itself but also to its serious complications, including damage to the kidneys, eyes, and nerves.

While insulin replacement remains the cornerstone of Type 1 diabetes treatment, researchers have begun exploring whether certain oral medications used in Type 2 diabetes might offer additional benefits in Type 1—specifically by restoring mitochondrial health.

A recent scoping review examined this question by searching through nearly 1,000 published studies. Researchers found that preclinical laboratory studies suggest two medications—metformin and empagliflozin—may help repair mitochondrial dysfunction in Type 1 diabetes. Both drugs appear to work by activating a cellular repair pathway called AMPK, which triggers mitochondrial maintenance and regeneration while preventing harmful mitochondrial fragmentation.

However, these findings come from laboratory and animal studies, not human trials. The review's authors were clear that clinical translation remains speculative and requires rigorous testing before any recommendations can be made.

The research landscape is shifting. As scientists better understand the role of mitochondrial damage in Type 1 diabetes, they're identifying new targets for treatment beyond insulin alone. The early promise of metformin and empagliflozin suggests that adjunctive therapy—using additional drugs alongside insulin—might eventually help protect cells from some of the damage Type 1 diabetes causes.

But 'early promise' is crucial language. Laboratory findings don't always translate to real-world benefit in patients. Clinical trials are essential to determine whether these medications are safe and effective as add-ons to standard insulin therapy in Type 1 diabetes, and whether they actually improve outcomes for patients.

For now, insulin remains the proven, life-saving treatment for Type 1 diabetes. Ongoing research into mitochondrial function represents an important frontier in understanding and potentially addressing the disease's underlying biology.

Source: Life (Basel, Switzerland). Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.